At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 33 enrolled
Drug / intervention
GSK3858279 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, Target Engagement and Immunogenicity of a Single Subcutaneous Dose of GSK3858279 Administered to Healthy Caucasian, Chinese and Japanese Participants
In Brief
A Phase 1 clinical trial evaluating GSK3858279 and Placebo for Pain. Completed, enrolled 33 participants across 2 sites.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), target engagement (TE) and immunogenicity of GSK3858279 when administered to healthy Caucasian, Chinese and Japanese participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesAustralia
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedDec 2021
Enrollment StartFeb 2022
Primary CompletionFeb 2023
Study CompletionApr 2023
TodayJul 2026
First PostedDec 30, 2021
Enrollment StartFeb 14, 2022
Primary CompletionFeb 10, 2023
Study CompletionApr 17, 2023
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 4.5 years ago
Interventions
GSK3858279drug
GSK3858279 will be administered
Placebodrug
Placebo will be administered